Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.28
NAS:IPXL's Cash-to-Debt is ranked lower than
80% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. NAS:IPXL: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:IPXL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28  Med: N/A Max: No Debt
Current: 0.28
Equity-to-Asset 0.43
NAS:IPXL's Equity-to-Asset is ranked lower than
74% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NAS:IPXL: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:IPXL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.54 Max: 0.84
Current: 0.43
0.2
0.84
Piotroski F-Score: 3
Altman Z-Score: 1.00
Beneish M-Score: -2.03
WACC vs ROIC
10.54%
-10.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -21.97
NAS:IPXL's Operating Margin % is ranked lower than
85% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. NAS:IPXL: -21.97 )
Ranked among companies with meaningful Operating Margin % only.
NAS:IPXL' s Operating Margin % Range Over the Past 10 Years
Min: -23.01  Med: 14.59 Max: 44.72
Current: -21.97
-23.01
44.72
Net Margin % -19.93
NAS:IPXL's Net Margin % is ranked lower than
84% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NAS:IPXL: -19.93 )
Ranked among companies with meaningful Net Margin % only.
NAS:IPXL' s Net Margin % Range Over the Past 10 Years
Min: -24.15  Med: 11.2 Max: 46
Current: -19.93
-24.15
46
ROE % -17.62
NAS:IPXL's ROE % is ranked lower than
84% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.12 vs. NAS:IPXL: -17.62 )
Ranked among companies with meaningful ROE % only.
NAS:IPXL' s ROE % Range Over the Past 10 Years
Min: -26.51  Med: 11.34 Max: 125.75
Current: -17.62
-26.51
125.75
ROA % -9.26
NAS:IPXL's ROA % is ranked lower than
82% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. NAS:IPXL: -9.26 )
Ranked among companies with meaningful ROA % only.
NAS:IPXL' s ROA % Range Over the Past 10 Years
Min: -11.98  Med: 7.63 Max: 38.8
Current: -9.26
-11.98
38.8
ROC (Joel Greenblatt) % -69.08
NAS:IPXL's ROC (Joel Greenblatt) % is ranked lower than
85% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. NAS:IPXL: -69.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:IPXL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -33.28  Med: 40.78 Max: 236.29
Current: -69.08
-33.28
236.29
3-Year Revenue Growth Rate 12.00
NAS:IPXL's 3-Year Revenue Growth Rate is ranked higher than
68% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. NAS:IPXL: 12.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:IPXL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 37.15 Max: 204.1
Current: 12
0
204.1
3-Year EBITDA Growth Rate -3.10
NAS:IPXL's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. NAS:IPXL: -3.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:IPXL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -10.9 Max: 61.7
Current: -3.1
0
61.7
3-Year EPS without NRI Growth Rate -13.00
NAS:IPXL's 3-Year EPS without NRI Growth Rate is ranked lower than
75% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. NAS:IPXL: -13.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:IPXL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.2  Med: -6.3 Max: 55.1
Current: -13
-32.2
55.1
GuruFocus has detected 3 Warning Signs with Impax Laboratories Inc $NAS:IPXL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:IPXL's 10-Y Financials

Financials (Next Earnings Date: 2017-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

IPXL Guru Trades in Q1 2016

Joel Greenblatt 478,620 sh (+2317.15%)
Jim Simons 117,700 sh (+40.45%)
Paul Tudor Jones 28,203 sh (+28.41%)
Eaton Vance Worldwide Health Sciences Fund 773,500 sh (unchged)
NWQ Managers 190,660 sh (-3.89%)
Alan Fournier 2,083,074 sh (-10.27%)
» More
Q2 2016

IPXL Guru Trades in Q2 2016

Paul Tudor Jones 52,408 sh (+85.82%)
Joel Greenblatt 733,848 sh (+53.33%)
Jim Simons Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
NWQ Managers 186,406 sh (-2.23%)
Alan Fournier 1,949,569 sh (-6.41%)
» More
Q3 2016

IPXL Guru Trades in Q3 2016

Jim Simons 177,700 sh (New)
Steven Cohen 566,500 sh (New)
NWQ Managers 1,068,795 sh (+473.37%)
Alan Fournier Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 16,230 sh (-69.03%)
» More
Q4 2016

IPXL Guru Trades in Q4 2016

Jim Simons 1,093,002 sh (+515.08%)
Paul Tudor Jones 77,612 sh (+378.20%)
Steven Cohen 581,400 sh (+2.63%)
NWQ Managers 1,026,237 sh (-3.98%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:EVTCY, NAS:DEPO, NAS:SGYP, NAS:MNTA, OTCPK:TWMJF, OTCPK:NPPNY, NAS:EGRX, NYSE:LCI, NAS:SUPN, NAS:HRTX, NAS:AMPH, NAS:SCMP, NAS:SCLN, OTCPK:ACBFF, NAS:ACET, NAS:PCRX, NAS:LBIO, OTCPK:ARSUF, OTCPK:OWCP, NAS:RIGL » details
Traded in other countries:ILR.Germany,
Impax Laboratories Inc is a technology-based, specialty pharmaceutical company. It is engaged in the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development.

Impax Laboratories Inc is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as generics in addition to the development and marketing of branded products. It operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. It develops, manufactures, sells and distributes specialty generic pharmaceuticals. The Global Division develops, manufactures, sells and distributes generic pharmaceutical products mainly through four sales channels: the Global products sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, retail drug chains and others; the Private Label sales channel, for generic pharmaceutical over-the-counter and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the Rx Partner sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements and the OTC Partner sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Ltd. Its Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system (CNS) disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. It markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Its main competitors are Teva Pharmaceutical Industries Ltd., Actavis, Inc., Mylan Inc., Ranbaxy Laboratories Ltd., Lannett Company, Inc., Sandoz, Inc.,

Ratios

vs
industry
vs
history
Forward PE Ratio 10.64
IPXL's Forward PE Ratio is ranked higher than
81% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.82 vs. IPXL: 10.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.15
IPXL's PB Ratio is ranked higher than
85% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. IPXL: 1.15 )
Ranked among companies with meaningful PB Ratio only.
IPXL' s PB Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.36 Max: 4.3
Current: 1.15
0.99
4.3
PS Ratio 1.10
IPXL's PS Ratio is ranked higher than
79% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. IPXL: 1.10 )
Ranked among companies with meaningful PS Ratio only.
IPXL' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.52 Max: 5.73
Current: 1.1
0.95
5.73
Price-to-Free-Cash-Flow 11.30
IPXL's Price-to-Free-Cash-Flow is ranked higher than
81% of the 185 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.92 vs. IPXL: 11.30 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IPXL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.06  Med: 15.98 Max: 103.25
Current: 11.3
2.06
103.25
Price-to-Operating-Cash-Flow 7.43
IPXL's Price-to-Operating-Cash-Flow is ranked higher than
83% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.34 vs. IPXL: 7.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IPXL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.84  Med: 13.74 Max: 4004
Current: 7.43
1.84
4004
Shiller PE Ratio 13.46
IPXL's Shiller PE Ratio is ranked higher than
93% of the 157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.81 vs. IPXL: 13.46 )
Ranked among companies with meaningful Shiller PE Ratio only.
IPXL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.59  Med: 26.8 Max: 506.2
Current: 13.46
11.59
506.2
Current Ratio 2.09
IPXL's Current Ratio is ranked lower than
53% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. IPXL: 2.09 )
Ranked among companies with meaningful Current Ratio only.
IPXL' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.18 Max: 10.65
Current: 2.09
1.12
10.65
Quick Ratio 1.59
IPXL's Quick Ratio is ranked lower than
54% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. IPXL: 1.59 )
Ranked among companies with meaningful Quick Ratio only.
IPXL' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 2.76 Max: 10.07
Current: 1.59
0.63
10.07
Days Inventory 65.72
IPXL's Days Inventory is ranked higher than
78% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. IPXL: 65.72 )
Ranked among companies with meaningful Days Inventory only.
IPXL' s Days Inventory Range Over the Past 10 Years
Min: 50.25  Med: 90.64 Max: 162.44
Current: 65.72
50.25
162.44
Days Sales Outstanding 96.30
IPXL's Days Sales Outstanding is ranked lower than
65% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. IPXL: 96.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.05  Med: 77.94 Max: 189.27
Current: 96.3
34.05
189.27
Days Payable 28.84
IPXL's Days Payable is ranked lower than
87% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. IPXL: 28.84 )
Ranked among companies with meaningful Days Payable only.
IPXL' s Days Payable Range Over the Past 10 Years
Min: 20.18  Med: 45.55 Max: 189.99
Current: 28.84
20.18
189.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
IPXL's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. IPXL: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPXL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86.4  Med: -6.4 Max: -1.7
Current: -2.1
-86.4
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.86
IPXL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
88% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. IPXL: 0.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IPXL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.34 Max: 3.37
Current: 0.86
0.61
3.37
Price-to-Median-PS-Value 0.44
IPXL's Price-to-Median-PS-Value is ranked higher than
93% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. IPXL: 0.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IPXL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53  Med: 1.4 Max: 32
Current: 0.44
0.53
32
Earnings Yield (Greenblatt) % -15.60
IPXL's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. IPXL: -15.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IPXL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 9.3 Max: 56
Current: -15.6
0.1
56
Forward Rate of Return (Yacktman) % -1.21
IPXL's Forward Rate of Return (Yacktman) % is ranked lower than
69% of the 353 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.48 vs. IPXL: -1.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IPXL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21.4  Med: 3.5 Max: 90.5
Current: -1.21
-21.4
90.5

More Statistics

Revenue (TTM) (Mil) $908.1
EPS (TTM) $ -2.54
Beta1.15
Short Percentage of Float6.49%
52-Week Range $11.65 - 37.20
Shares Outstanding (Mil)73.87

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 842 965 1,058 1,030
EPS ($) 1.31 1.46 1.91 1.83
EPS without NRI ($) 1.31 1.46 1.91 1.83
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:IPXL

Headlines

Articles On GuruFocus.com
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity Nov 27 2015 
Kyle Bass Goes Fishing for These 3 New Holdings Nov 26 2015 
Alan Fournier's Highest Performing Stocks Jul 15 2015 
Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 

More From Other Websites
Zacks.com featured highlights: Applied Materials, General Motors, Citizens Financial Group, Chicago... Feb 22 2017
7 Low Price-to-Cash-Flow Stocks for Assured Returns Feb 21 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Impax Laboratories, Inc. for... Feb 15 2017
Zacks.com featured highlights: General Motors, Citizens Financial Group, Impax Laboratories and... Feb 06 2017
ETFs with exposure to Impax Laboratories, Inc. : February 3, 2017 Feb 03 2017
7 Stocks You Should Sell Right Now Feb 02 2017
Impax Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IPXL-US : February... Feb 02 2017
Blog Coverage Pfizer Reported Positive Results for Mid-stage Trial for C. difficile Vaccine Jan 27 2017
Impax to Report Fourth Quarter and Full Year 2016 Results on March 1, 2017 Jan 25 2017
U.S. reaches settlement with Endo on pay-for-delay charges Jan 23 2017
FTC settles pay-for-delay lawsuit, files two related complaints Jan 23 2017
Is Impax a Great Stock for Value Investors? Jan 19 2017
CVS takes on Mylan’s EpiPen with much cheaper version of an alternative Jan 15 2017
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks... Jan 13 2017
Biotech Premarket Movers: SGMO, IPXL, PTLA Jan 13 2017
Cheaper Epinephrine: Spend Way Less With This EpiPen Alternative Jan 12 2017
UPDATE 1-CVS slashes price of Impax's EpiPen rival Jan 12 2017
CVS slashes price of Impax's emergency allergy shot Jan 12 2017
Mylan Crushed by Trump, Cigna and CVS -- All In Two Days Jan 12 2017
[$$] Cigna Drops EpiPen Coverage for Generic Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)